Your browser doesn't support javascript.
loading
Perioperative Considerations for Evolving Artificial Pancreas Devices.
Long, Micah T; Coursin, Douglas B; Rice, Mark J.
Afiliación
  • Long MT; From the Departments of Anesthesiology.
  • Coursin DB; From the Departments of Anesthesiology.
  • Rice MJ; Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Anesth Analg ; 128(5): 902-906, 2019 05.
Article en En | MEDLINE | ID: mdl-30198923
Type 1 diabetes mellitus is a lifelong condition. It requires intensive patient involvement including frequent glucose measurements and subcutaneous insulin dosing to provide optimal glycemic control to decrease short- and long-term complications of diabetes mellitus without causing hypoglycemia. Variations in insulin pharmacokinetics and responsiveness over time in addition to illness, stress, and a myriad of other factors make ideal glucose control a challenge. Control-to-range and control-to-target artificial pancreas devices (closed-loop artificial pancreas devices [C-APDs]) consist of a continuous glucose monitor, response algorithm, and insulin delivery device that work together to automate much of the glycemic management for an individual while continually adjusting insulin dosing toward a glycemic target. In this way, a C-APD can improve glycemic control and decrease the rate of hypoglycemia. The MiniMed 670G (Medtronic, Fridley, MN) system is currently the only Food and Drug Administration-cleared C-APD in the United States. In this system, insulin delivery is continually adjusted to a glucose concentration, and the patient inputs meal-time information to modify insulin delivery as needed. Data thus far suggest improved glycemic control and decreased hypoglycemic events using the system, with decreased need for patient self-management. Thus, the anticipated use of these devices is likely to increase dramatically over time. There are limited case reports of safe intraoperative use of C-APDs, but the Food and Drug Administration has not cleared any device for such use. Nonetheless, C-APDs may offer an opportunity to improve patient safety and outcomes through enhanced intraoperative glycemic control. Anesthesiologists should become familiar with C-APD technology to help develop safe and effective protocols for their intraoperative use. We provide an overview of C-APDs and propose an introductory strategy for intraoperative study of these devices.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistemas de Infusión de Insulina / Páncreas Artificial / Diabetes Mellitus Tipo 1 / Periodo Perioperatorio / Hipoglucemia Límite: Humans Idioma: En Revista: Anesth Analg Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sistemas de Infusión de Insulina / Páncreas Artificial / Diabetes Mellitus Tipo 1 / Periodo Perioperatorio / Hipoglucemia Límite: Humans Idioma: En Revista: Anesth Analg Año: 2019 Tipo del documento: Article
...